Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
10.7M
-
Shares change
-
+10.7M
-
Total reported value, excl. options
-
$205M
-
Value change
-
+$205M
-
Number of buys
-
48
-
Price
-
$19.15
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q2 2019
48 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2019.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.7M shares
of 80M outstanding shares and own 13.34% of the company stock.
Largest 10 shareholders include venBio Partners LLC (3.95M shares), Redmile Group, LLC (1.17M shares), Cormorant Asset Management, LP (768K shares), JANUS HENDERSON GROUP PLC (761K shares), BVF INC/IL (648K shares), HILLHOUSE CAPITAL ADVISORS, LTD. (425K shares), BOXER CAPITAL, LLC (397K shares), WELLINGTON MANAGEMENT GROUP LLP (332K shares), HILLHOUSE CAPITAL MANAGEMENT, LTD. (298K shares), and Rock Springs Capital Management LP (225K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.